HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gopinathan, G. Articles by Calne, D. B. Search for Related Content PubMed PubMed Citation Articles by Gopinathan, G. Articles by Calne, D. B.

Lisuride in parkinsonism

From the Experimental Therapeutics Branch, IRP (Dr.s Gopinathan, Teräväinen, Ward, and Calne), and the Office of Biometry and Field Studies (Dr. Dambrosia), NINCDS, and the Laboratory of Neurophysiology (Drs. Sanes, Stuart, and Evarts), NIMH, Bethesda, MD.

Address correspondence and reprint requests to Dr. Calne, Clinical Director, NINCDS, Building 10, Room 6D20, National Institutes of Health, Bethesda, MD 20205.

we studied the actions of lisuride, a dopaminergic ergot derivative, in 20 parkinsonian patients. When the dose was increased gradually, most patients tolerated up to 5 mg daily. Clinical assessment and objective, computer-assisted evaluation revealed improvement in akinesia, rigidity and tremor. Adverse reactions were similar to those seen with levodopa and bromocriptine, but somnolence tended to occur more often with lisuride.

Accepted for publication June 17, 1980.